The K-EXP™ platform enables direct access to interstitial fluid for molecular measurement at the source
Partnership supports regulatory, clinical, and commercial expansion across Japan and Asia-Pacific
[ MIAMI, FL AND TOKYO, JAPAN / ACCESS Newswire ] – KIFFIK Biomedical today announced a strategic alliance with HekaBio K.K. to expand access to interstitial fluid (ISF) across Japan and key Asia-Pacific markets.
ISF surrounds living cells and reflects real-time biological activity at the tissue level – where molecular signaling, immune response, and disease progression originate. KIFFIK’s K-EXP™ platform is designed to access molecular signals directly from interstitial fluid – before dilution in the bloodstream.
The collaboration will focus on regulatory strategy, scientific advisory development, and strategic partnerships with pharmaceutical, diagnostic, and technology companies throughout the region.
Under the agreement, HekaBio will support KIFFIK’s regulatory strategy in Japan, act as a local strategic advisor for market entry, and assist in establishing clinical and commercial partnerships across Japan and Korea.
KIFFIK’s K-EXP™ platform has generated data demonstrating the ability to detect biomarkers directly in human and animal ISF across multiple biological contexts – such as oncology, cardiology, neurology, and dermatology – with low-abundance and early-stage signals not fully captured in blood.
Access to ISF has the potential to expand how biology is measured across diagnostics, drug development, and continuous health monitoring.
Japan represents one of the world’s most advanced healthcare markets, with leading pharmaceutical companies, academic institutions, and a highly developed regulatory environment.
KIFFIK is initiating select partnerships with pharmaceutical, diagnostics, and consumer health leaders to define early applications and integration pathways for ISF-based molecular access across oncology, dermatology, metabolic disease, and continuous biological monitoring.
About KIFFIK Biomedical
KIFFIK Biomedical is developing a platform designed to access molecular information directly from interstitial fluid (ISF), enabling new approaches to diagnostics, drug development, and continuous biological monitoring. The company is building technology intended to unlock real-time insight into human biology across multiple healthcare applications. Headquartered in Miami, Florida, KIFFIK is focused on expanding access to tissue-level molecular information that will power the future of medicine. Learn more →
